‘Another burden’: RACGP rejects proposed PBS restrictions on diabetes drugs
The RACGP has rejected calls for the PBS listing for initiating GLP-1 receptor agonists to move to authority required amid concerns it will add to GPs’ workload.
At its most recent meeting in March, the PBAC published draft recommendations following a review of the PBS criteria for diabetes medications.
These included making the GLP-1 receptor agonists (RAs) semaglutide and dulaglutide authority required when initiating therapy “for all indications”, but maintaining streamlined authority for continuing treatment.
“In making this recommendation, the PBAC considered the high use of GLP-1 RAs outside of the PBS restrictions, their high-cost versus comparator treatments and the administrative burden on prescribers associated with telephone/electronic authorities,” it said.
